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Introduction
Insulin is produced by the β-cells of the pancreas and regu-
lates cellular uptake of glucose from the blood. Type-1 diabe-
tes mellitus (T1DM) is the result of autoimmune destruction of 
pancreatic β-cells resulting in insulin deficiency and without 
prompt treatment patients may develop life threatening dia-
betic ketoacidosis. In these patients, it is imperative to exert 
tight glycemic control in order to prevent numerous macro-
vascular and microvascular complications including cardio-
vascular disease, renal disease, neuropathy or retinopathy. 
Progress in the pharmacology of insulin replacement has led 
to the development of new insulin formulations with improved 
pharmacokinetic and pharmacodynamic properties. How-
ever, despite this, patients with T1DM who require painful 
daily injections frequently expose themselves to hypoglycae-
mic episodes.1 In addition, adequate control of blood sugar 
levels is often difficult because synthetic insulin injections are 
not able to replicate the glucose regulatory function of normal 
islet cells.2 Currently, transplantation of cadaveric pancreatic 
islets is the preferred cell replacement therapy for T1DM.3 
However, this approach is limited by the need for immune 
suppression and a shortage of donor tissue suitable for trans-
plantation. Other sources of surrogate cells that have been 
considered include pluripotent embryonic stem cells,4,5 ex 
vivo expansion of β-cells;6 use of endocrine progenitor cells,7 
transdifferentiation of liver and intestinal cells8,9 or bone mar-
row mesenchymal stem cells.10 It is, however, now recognized 
that embryonic or bone marrow derived stem cells harbor the 
greatest potential for cell replacement strategy as they can 
be expanded to therapeutically relevant numbers and has the 
plasticity to generate most cell types of the body.
The process by which the pancreas arises from the 
definitive endoderm derived primitive gut tube is extensively 
defined in the literature. During development of the pan-
creas, the dorsal and ventral protrusion of the primitive gut 
epithelium gives rise to the endodermal germ layer where 
sonic hedgehog signaling is suppressed by activin A and 
basic fibroblast growth factor (bFGF) to allow development 
of the definitive endoderm.11 Noggin, epidermal growth fac-
tor (EGF), bFGF further directs differentiation towards pan-
creatic and duodenal homeobox gene-1 (PDX1) expressing 
posterior foregut endodermal cells.12 PDX1 controls the bal-
ance between exocrine and endocrine cells where it allows 
the expansion of an undifferentiated pancreatic progenitor 
population which can either be directed towards α-pancreatic 
or δ-pancreatic cells.13–15 Neurogenin 3 and NeuroD initi-
ates progression towards β-cells from the pancreatic endo-
derm. NKX6-1 coordinates β-cell specific islet development 
together with v-maf musculoaponeurotic fibrosarcoma onco-
gene homolog A (MafA) (a β-cell specific transcription factor 
that binds to RIPE3b, a conserved enhancer element that 
regulates expression of insulin) for functional maturation and 
acquisition of glucose sensitivity.16,17
By using a sequential cocktail of growth factors and bio-
active small molecules, D’Amour et al., successfully drove 
human embryonic stem cells through key developmental 
steps of the pancreas, including the definitive endodermal 
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Upon functional loss of insulin producing islet β-cells, some patients with diabetes become dependent on life-long insulin 
supplementation therapy. Bioengineering surrogate insulin producing cells is an alternative replacement strategy. We have 
developed a novel approach using short-activating RNA oligonucleotides to differentiate adult human CD34+ cells into insulin-
secreting cells. By transfecting RNA to increase transcript levels of the master regulator of insulin biosynthesis, v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), several pancreatic endodermal genes were upregulated during 
the differentiation procedure. These included Pancreatic and duodenal homeobox gene-1 (PDX1), Neurogenin 3, NeuroD, and 
NK6 homeobox 1 (NKX6-1). Differentiated CD34+ cells also expressed glucokinase, glucagon-like peptide 1 receptor (GLP1R), 
sulfonylurea receptor-1 (SUR1) and phogrin—all essential for glucose sensitivity and insulin secretion. The differentiated cells 
appropriately processed C-peptide and insulin in response to increasing glucose stimulation as shown by enzyme-linked 
immunosorbent assay (ELISA), fluorescence-activated cell sorting analysis, western blotting, and immunofluorescence staining. 
We provide a new approach using short-activating RNA in developing insulin producing surrogate cells for treating diabetes.
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stage through to the foregut; pancreatic endodermal; endo-
crine progenitor stage; and finally to pancreatic β-cells.12,18–20 
Despite creating differentiated cells expressing insulin levels 
similar to that of human islet cells, they only released biologi-
cally active insulin in response to various secretagogues but 
not in response to glucose. As the major limitations of using 
embryonic stem cells in clinical therapy include their contro-
versial source and tumorigenic potential,13,21 their usefulness 
for regenerative therapy in the context of chronic non-malig-
nant disease is still contentious. Human adult bone marrow 
derived stem cells, in contrast with their recently identified 
pluripotency22 and proven safety profile, are an attractive 
alternative to embryonic stem cells. Adult human stem cells 
isolated from the bone marrow can, under appropriate con-
ditions, differentiate into multiple cell types including carti-
lage, bone and adipose tissue.13 Chandra et al.,23 recently 
demonstrated that human adipose tissue derived stem cells 
exposed intermittently between serum rich and serum-free 
medium in the presence of differentiation factors, were suc-
cessfully differentiated into functional islet like aggregates 
that synthesized C-peptide and insulin in a glucose depen-
dent manner. Like the other studies mentioned, certain 
non-GMP (good manufacturing practice) compliant factors 
including β-mercaptoethanol used in the differentiation pro-
tocol currently limits clinical applicability.23 More recently, 
targeted activation of crucial pancreatic transcription factors 
successfully generated insulin-secreting cells;24–27 however, 
because these methods depend largely on the use of lenti-
viral vectors, their potential for clinical use is restrained.28–31
In human cells, it has been reported that short RNA to the 
promoter regions of certain genes can activate expression at 
the transcriptional level without altering the genome.32,33 This 
process has been referred to RNA activation (RNAa), and is 
shown to be conserved in other mammals including mice, 
rats and primates.34 Although the exact mechanism of action 
is still not fully defined, it is suggested that naturally occur-
ring antisense transcripts from the same gene loci or within 
close vicinity are able to recruit argonaute proteins and his-
tones methytransferases (proteins responsible for epigenetic 
gene silencing). Short-activating RNAs (saRNAs) therefore 
may positively regulate transcription by targeting these anti-
sense molecules for degradation, resulting in upregulation of 
sense messenger RNA, thus reversing gene silencing.35–37 
On the basis of this principle, we have developed a method 
of designing saRNAs for positively regulating specific genes 
with the aim of reprogramming human adult stem cells. For 
this study, we have used a subpopulation of adherent CD34+ 
cells mobilized from normal adult human bone marrow as 
they are known to have multi-lineage differentiation potential. 
These adherent CD34+ cells have previously been character-
ized as having greater plasticity than the non-adherent popu-
lation as they express determinants specific for differentiation 
towards liver, pancreas, heart, muscle, and nerve cells.38,39 
We have successfully induced the differentiation of adherent 
CD34+ cells towards an endodermal pre-proinsulin express-
ing lineage using a serum-free culture system supplemented 
with a combination of GMP compliant differentiation factors 
traditionally used for culturing pancreatic endocrine cells 
(activin A, exendin-4, noggin, EGF, and bFGF). In addition, 
as it has recently been reported that saRNA oligonucleotides 
can mediate induction of endogenous pluripotency factors in 
human mesenchymal stem cells,40 the data presented here 
show for the first time that saRNA oligonucleotides designed 
to upregulate mRNA transcripts of the islet β-cell specific 
transcription factor, MafA profoundly influences the differen-
tiation of human adult CD34+ cells.
Results
Differentiation and characterization of CD34+ cells using 
defined factors and MafA saRNA
To recapitulate the series of gene activation that occurs 
during commitment of progenitor cells toward the pancre-
atic endodermal lineage, we used freshly isolated adherent 
adult human CD34+ cells as they display better multi-lineage 
potential.39 Adherent CD34+ cells were exposed to differen-
tiation factors defined for inducing insulin-expressing cells. 
This included activin A, exendin-4, noggin, EGF, and bFGF 
(Figure 1a). As cells grown under these conditions have pre-
viously been induced to express insulin, we also confirm that 
adherent CD34+ cells showed positive expression of PDX1, 
insulin, and Rfx6 (Figure 1b). These cells however did not 
respond to glucose stimulation (data not shown). To further 
enhance expression of insulin and its specific transcription 
factors, the differentiated cells were cultured in a GMP (good 
manufacturing practice) grade serum-free medium and trans-
fected at days 2, 5, and 8 with short-activating RNAs (saR-
NAs) designed specifically to target the islet β-cell master 
regulator MafA (Figure 1a). Here, we established that the 
optimal time point to establish glucose responsiveness was 
at day 12 after which the stability of these cells in vitro was 
severely compromised (Supplementary Figure S1a). Total 
RNA from the cultured cells was isolated at days 0, 3, 6, 9, 
and 12 for reverse transcription and analysis of messenger 
RNA levels. The primer pairs for insulin were selected to 
amplify exons 2 and 3 of the human insulin gene. The prod-
ucts therefore revealed two bands at 343 bp and 307 bp (Fig-
ure 1b,c). The 343 bp fragment corresponds to the human 
insulin mRNA spliced at position +3397 to generate full 
pre-proinsulin mRNA. The 307 fragment is the product of an 
alternative splicing pathway characterized at splice junctions 
+3433 and +3522 of the human insulin gene.41,42 The human 
pancreatic islet cells express insulin mRNA in its shorter form 
when compared with its expression in non-pancreatic cells 
due to the specificity of the splicing machinery in different cell 
types. Both 341 bp and 307 bp variants however go through 
complete conversion into insulin. A semi-quantitative profile 
of the saRNA-transfected cells showed significant upregu-
lation of the key insulin specific transcription factors PDX1, 
Rfx6, MafA, and insulin by day 3 (D3) in MafA-transfected 
cells where this was maintained for 12 days (D12) (Figure 
1c,d–g). Expression of these genes in MafA-transfected 
cells were sustained until day 12 (D12) compared with D9 in 
untransfected cells (Figure 1d–g).
Expression level of pancreatic markers in MafA- 
transfected cells
To consolidate this observation, a quantitative analysis of 
the genes was performed using untransfected and MafA-
transfected cells at D12 and compared with undifferentiated 
CD34+ cells. MafA-transfected cells contained a significant 
www.moleculartherapy.org/mtna
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increase in the expression of PDX1 (Figure 2a), Neurogenin 
3 (NEUROG3) (Figure 2b), NeuroD (NEUROD1) (Figure 
2c), NKX6-1 (Figure 2d), MafA (Figure 2e), glucokinase 
(GCK) a hexokinase enzyme which phosphorylates glucose 
in the initial steps of glucose metabolism43 (Figure 2f), glu-
cagon-like peptide 1 receptor (GLP1R), an important factor 
for insulin secretion (Figure 2g),44 sulfonylurea receptor-1 
(SUR1), ABCC8, a potassium channel (K-ATP) regulator 
of insulin secretion (Figure 2h),45,46 Phogrin (PTPRN2) an 
insulin granule membrane protein (Figure 2i),47 and INS 
(Figure 2j). To confirm that the target gene effect caused by 
the saRNA was not only specific to CD34+ cells, we demon-
strated that transfection of the oligonucleotide into a hepa-
tocyte cell line (HepG2) also induced a positive regulation 
Figure 1 Differentiation procedure of CD34+ cells in the presence of MafA saRNA. (a) A flow diagram of the differentiation protocol 
including addition of the growth hormones and transfection of the short-activating RNA (saRNA) oligonucleotide specific to MafA. (b) Semi-
quantitative PCR analysis of reverse-transcribed mRNA isolated from cultured CD34+ cells at days 0, 3, 6, 9, and 12, and (c) analysis of 
reverse-transcribed mRNA isolated from MafA-transfected CD34+ cells. Positive PCR control used was total human adult pancreatic RNA. 
(d–g) Semi-quantitative analysis of mRNA expression levels of (d) PDX1, (e) RFX6, (f) MafA, and (g) INS, respectively from samples as 
mentioned in b and c. Values are mean ± SEM of five independent differentiation experiments. A paired t-test at 95% confidence gave a 
significant difference in expression values between untransfected and MafA-transfected cells for RFX6 at D12 (P = 0.03) and at Day 9 (P 
= 0.001) and D12 (P = 0.007) and for MafA. MafA, v-maf musculoaponeurotic fibrosarcoma oncogene homologue; PDX1, Pancreatic and 
Duodenal homeobox 1; RFX6, Regulatory Factor x box 6.
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of PDX1 and Neurogenin 3 (Supplementary Figure S1b). 
All SYBR green primer sets were validated against human 
pancreatic RNA (Supplementary Figure S1c).
Glucose response of MafA-transfected cells
We then investigated whether regulation of the transcript 
levels in the MafA-transfected cells would be sensitive to 
glucose treatment. D12 MafA-transfected cells were treated 
with 16 mmol/l glucose for 3 hours. Total RNA was then 
extracted for quantitative RT-PCR where we observed posi-
tive regulation in mRNA levels of the relevant transcription 
factors when compared with cells without glucose treatment 
(Figure 3a). Scatter plot fluorescence-activated cell sorting 
analysis (Figure 3b) demonstrated a significant increase in 
staining for insulin and C-peptide in MafA-transfected cells 
treated with glucose. Fluorescence-activated cell sorting 
analysis from a total of five independent experiments dem-
onstrated a significant increase in expression of insulin and 
Figure 2 Upregulation of key transcriptional factors in the presence of MafA saRNA. mRNA levels of (a) PDX1, (b) NEUROG3, 
(c) NEUROD1, (d) NKX6-1, (e) MafA, (f) GCK, (g) GLP1R, (h) SUR1 (K-ATP component (sulfonyl urea receptor, the ATP sensitive potassium 
channel), ABCC8, (i) PTPRN2, and (j) INS. Values are mean ± SEM of three independent experiments run in triplicate and shows expression 
relative to undifferentiated CD34+ cells. *P < 0.005; **P < 0.0001; ***P < 0.00001, paired Student’s t-test, two-tailed at 95% CI. GCK, 
glucokinase; GLP1R, glucagon-like peptide 1 receptor; INS, insulin; MafA, v-maf musculoaponeurotic fibrosarcoma oncogene homologue; 
NEUROD1, NeuroD; NEUROG3, Neurogenin 3; PDX1, Pancreatic and Duodenal homeobox 1; PTPRN2, Phogrin; SUR1, sulfonylurea 
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C-peptide in MafA-transfected cells by over 12% relative to 
untransfected cells. The percentage of positive expressing 
cells increased to over 30% in glucose-treated MafA-trans-
fected cells relative to untreated MafA-transfected cells 
(Figure 3c). Individual flow cytometry data for untransfected 
CD34+ cells grown in the differentiation media is also shown 
for insulin and C-peptide (Supplementary Figure S2a,b, 
respectively).
Insulin and C-peptide release from MafA-differentiated 
cells
Having confirmed that MafA-transfected cells contained 
increasing levels of factors for insulin secretion by D12, we 
next determined whether they could respond biologically 
to increasing concentrations of glucose. An enzyme-linked 
immunoabsorbent assay (ELISA) specific for human insulin 
and C-peptide was performed. D12 MafA-transfected cells 
alongside D12-undifferentiated cells (control) were exposed 
initially to a low concentration of glucose (2.8 mmol/l) for 2 
hours followed by exposure to a high concentration of glu-
cose (16 mmol/l) for 3 hours (Figure 4a). The culture media 
was then isolated for the ELISA onto 96-well plates. The data 
suggest that MafA-transfected cells secreted substantially 
more insulin (up to 18 pM/L) and C-peptide (up to 35 ηg/ml) 
when exposed to high concentrations of glucose (Figure 4a). 
Total protein extracts from these cells were then separated 
by SDS-PAGE for a western blot to confirm that biologically 
active insulin (with both α and β chains) was expressed 
 (Figure 4b). Immunofluorescent staining using antibodies 
specific for human insulin and C-peptide demonstrated a 
positive staining when MafA-transfected cells were stimu-
lated with glucose (Figure 4c; Supplementary Figure S3a). 
We also observed accumulation of granular secretory like 
granules in the cytoplasm of MafA-transfected cells (Supple-
mentary Figure S3b)
Taken together, we demonstrate here that a GMP compli-
ant differentiation protocol using saRNAs in a serum-free 
environment enriched with growth factors and cytokines tra-
ditionally used for differentiation of insulin-secreting cells is 
sufficient to differentiate adult CD34+ cells towards one that 
expresses transcriptional factors specific for the endodermal 
pancreatic lineage.
Figure 3 Glucose response in MafA-transfected cells. (a) MafA-transfected cells were exposed to 16 mmol/l of glucose for 3 hours and 
analyzed for transcripts determined to be necessary for insulin secretion. Expression levels of PDX1, NEUROD1, NKX6-1, GLP1R, MafA, INS, 
and PTPRN2 increased up to 1.5-fold or more. Values represent the mean ± SEM of three independent experiments in triplicate. *P < 0.005; 
**P < 0.0001, paired Student’s t-test, two-tailed at 95% CI. (b) Representative scatter plot of individual FACS-analyzed cells probed with insulin 
and C-peptide relative to control isotype IgG. (c) FACS-derived expression ratio from five independent differentiation experiments suggests 
that although there is no significant difference in expression between insulin or C-peptide, levels of both significantly increase (in excess 
of 35%) when MafA-transfected cells are exposed to glucose. Results are mean and SEM of five independent differentiation experiments. 
Mann–Whitney test was performed at 95% confidence. FACS, fluorescence-activated cell sorting; GLP1R, glucagon-like peptide 1 receptor; 
INS, Insulin; MafA, v-maf musculoaponeurotic fibrosarcoma oncogene homologue; NEUROD1, NeuroD; NEUROG3, Neurogenin 3; PDX1, 
Pancreatic and Duodenal homeobox 1; PTPRN2, Phogrin.
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Discussion
The primary therapeutic goal of preventing complications 
associated with diabetes is to maintain a stable glycemic 
content by reconstitution of endogenous insulin secretion. 
Islet transplantation therefore presents a feasible therapeutic 
alternative for metabolically labile patients with T1DM; how-
ever, shortage of organ donors does not make this a practical 
option. Many attempts have been made to develop surrogate 
insulin-secreting cells using embryonic stem cells, organ 
derived stem cells or inducible pluripotent stem cells.
The basic methodology of pushing stem cells towards 
the pancreatic endodermal lineage has previously been 
described by other groups. The addition of activin A, 
exendin-4, noggin, EGF, and bFGF during stages of the 
differentiation process is known to drive stem cells towards 
an insulin-expressing phenotype.12,18–20 The current challenge 
however is the ability to maintain this expression to comple-
tion and generate cells that will respond to glucose using a 
GMP compliant serum-free method. This has not yet been 
achieved. We therefore demonstrate that a combination of 
GMP compliant growth factors and saRNA molecules can 
be used to transform human adult CD34+ cells into glucose 
sensitive and insulin-secreting cells. This novel use of saRNA 
oligonucleotides positively increases the transcript levels 
of MafA. Being the master switch for insulin expression in 
β-cells, MafA then induces expression of key endodermal 
endocrine factors including PDX1, Neurogenin 3 and NeuroD, 
MafA, glucokinase, glucagon-like peptide 1 receptor, SUR1-
KATP, and phogrin. These factors are essential in supporting 
Figure 4 Insulin and C-peptide release from MafA-transfected cells. (a) ELISA demonstrating MafA-transfected cells respond to glucose 
stimulation when compared with undifferentiated CD34+ cells (control). The culture media from control and from day 12 MafA-transfected 
cells were recovered following exposure of cells to low glucose (2.8 mmol/l) followed by high glucose (16 mmol/l) pulse. The media was then 
transferred onto immunoabsorbent ELISA plates specific for human insulin and human C-peptide. The data suggest that MafA-transfected cells 
are able to respond to a glucose gradient by secreting insulin. (b) Day 12 MafA-transfected cells that were treated with 16 mmol/l glucose from 
as mention in a were isolated for total protein extraction and SDS-PAGE separation. A western blot probed with an antibody specific to human 
insulin demonstrates the presence of biologically active insulin with its α and β chain. (c) Confocal microscopy of undifferentiated (control) and 
MafA-transfected cells with or without glucose treatment. Both control and MafA-transfected cells (with or without glucose treatment) were 
then costained with anti-insulin and anti C-peptide.
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glucose sensitivity and processing of insulin. This observa-
tion ties in with other reports by Wang et al. and Aramata et 
al. suggesting that the master regulatory potential of MafA 
can feasibly mediate transdifferentiation of progenitor cells 
towards an insulin secretory lineage.48,49 Moreover, our dif-
ferentiation protocol also suggests a potential to upregulate 
sensitivity to the incretin hormone, GLP1 which is important 
in promoting pancreatic endocrine cell growth, in stimulat-
ing insulin release in the post-prandial state and in expan-
sion of β-cell mass via islet cell neogenesis.44 Therefore, our 
approach may be a possible avenue towards restoration of 
glucose sensitivity for type-2 diabetes and one that will be 
further investigated.
At the current stage of this promising approach to gener-
ating glucose responsive cells from hematopoietic derived 
CD34+ cells, our procedure demonstrates that up to 35% of 
MafA-transfected cells responds to glucose and achieved an 
insulin secretion content of approximately 18 pM/L by day 12. 
The next challenge will be to meet the normal adult insulin 
requirement of 57–79 pM/L (between meals) and to estab-
lish how these cells behave functionally in vivo and whether 
they may require encapsulation strategies or micro chamber 
technology to enhance cell survival beyond 12 days following 
transplantation.50,51 Despite the numerous hurdles ahead, the 
work performed here represents a significant step forward 
towards developing a potentially useful clinical tool for recon-
stituting endogenous insulin secretion with reduced possi-
bility of rejection. Although this strategy may not completely 
remove the requirement for pharmacological insulin replace-
ment formulations, it may provide a baseline to reduce the 
risks associated with severe diabetes.
Materials and methods
CD34+ stem cell source. Granulocyte colony-stimulating 
factor–mobilized peripheral blood cells were obtained from 
leukaphereses processed by the Stem Cell Laboratory, 
Hammersmith Hospital. A total of five healthy donor patients 
undergoing mobilization for transplantation in allogeneic 
recipients were used where cells were in excess of clinical 
requirements. Blood samples were obtained with informed 
patient consent and approved by the Hammersmith Hospital 
Research Ethics Committee. We found that the response of 
the cells used in the differentiation procedure was similar for 
all the five healthy donors.
CD34+ stem cell isolation. Human-mobilized peripheral blood 
samples were diluted in a ratio of 1:4 in Hanks’ buffered saline 
solution (Gibco, Paisley, UK), the mononuclear cells were 
separated by centrifugation over a Lymphoprep (Axis-Shield, 
Dundee, UK) density gradient at 1,800 rpm for 30 minutes. The 
mononuclear cell fraction at the interface was aspirated and 
washed twice with HBSS, and finally with MACS buffer (Dul-
becco’s phosphate-buffered saline solution (DPBS) (Gibco) at 
pH 7.2 supplemented with 0.5% human serum albumin and 
2 mmol/l EDTA). CD34+ cells were isolated using a CD34+ 
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer’s protocol. Adherent CD34+ pro-
genitor cells were isolated as previously described with modi-
fication.38,39 Briefly, isolated CD34+ cells were added to 24-well 
tissue culture treated dishes (Nunc, Loughborough, UK) at a 
density of 2.5–5 × 105 cells in α-MEM medium to isolate the 
adherent CD34+ cell population. After 30 minutes incubation, 
non-adherent cells were removed and adherent cells were 
rinsed three times with PBS. The adherent CD34+ cell popula-
tion was grown in a serum-free medium-CellGro (CellGenix, 
Freiburg, UK) containing three cytokines: 250 ηg/ml of stem 
cell factor, 250 ηg/ml of interleukin-6, and 250 ηg/ml of interleu-
kin-3 (Invitrogen, Carlsbad, CA or CellGenix) in 0.5% penicil-
lin/streptomycin antibiotics. Cells were incubated at 37 °C in 
humidified 5% CO2 air.
Design of short-activating RNA oligonucleotides. The 
gene sequence of MafA was selected for designing short-
activating RNA molecules for its specific activation. Four 
parameters were used: (i) targeting gene annotations from 
UCSC RefSeq database; (ii) targeted sequence from anti-
sense RNA; (iii) promoter selection of antisense sequences; 
and (iv) identification of candidate short activating RNAs. 
First, the method downloads information about the target’s 
genomic location, orientation, and transcriptional structure 
from available databases (RefSeq at UCSC). Second, given 
a database of RNA transcripts with known read direction, 
such as the UCSC Spliced EST track, our method searches 
the database for transcripts that are antisense to and in the 
vicinity of the target gene. More specifically, the method iden-
tifies antisense transcripts that (a) overlap the target’s pro-
moter and the target mRNA’s 5′ end; (b) overlap the target 
mRNA; (c) are at most 20-100 kb upstream of the target’s 
transcription start site; or (d) are at most 20-100 kb down-
stream of the target’s poly-adenylation site. The method uses 
these four criteria as hierarchical filters such that if it finds 
antisense transcripts that for example satisfy criterion (a), 
the method does not consider the three other criteria. Third, 
based on the target’s transcription start site, the method 
downloads the antisense genomic sequence from a fixed 
size region upstream and downstream of the transcription 
start site. The typical region size used by the method is 500 
nts upstream and downstream of transcription start site, but 
larger or smaller sizes can also be used. Fourth, the method 
designs siRNAs that give effective and specific downregula-
tion of the antisense target sequence. The method (a) uses a 
siRNA design algorithm, such as GP boost,52 to identify can-
didate effective siRNAs; (b) removes all candidate siRNAs 
with aaaa, cccc, gggg, or uuuu motifs and GC content <20% 
or >55%; (c) removes all candidates that have Hamming dis-
tance less than two to all potential off-target transcripts; and 
(d) returns a given number of remaining non-overlapping siR-
NAs sorted by their predicted siRNA knockdown efficacy. The 
method returns the two highest scoring short activating RNAs 
for a given antisense target sequence. Paired short activating 
RNA oligonucleotides were annealed using 50 mmol/l Tris–
HCl, pH 8.0, 100 mmol/l NaCl and 5 mmol/l EDTA following a 
denaturation step at 90 °C followed by a gradual anneal step 
to room temperature.
Differentiation procedure. A flow diagram of the differentiation 
procedure is shown in (Figure 1a). The commencement of 
the differentiation protocol involved supplementing the adher-
ent subpopulation of hematopoietic adult CD34+ cells with 
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10 ηg/ml of activin A (Sigma, Poole, UK) and 2.5 mmol/l glucose 
(Sigma, St Louis, MO) into serum-free CellGro media (Cell-
Genix) containing Stem Cell Factor (Invitrogen), 250 ηg/ml 
of interleukin-3 and interleukin-6 (Invitrogen) in 0.5% penicil-
lin/streptomycin antibiotics for 72 hours at day 0. This was 
then followed by the addition of 11 mmol/l glucose, 5 ηg 
exendin-4 (Sigma, St Louis, MO), 50 ηg noggin (Sigma, St 
Louis, MO), 5 ηg bFGF (Sigma, St Louis, MO), and 5 ηg 
EGF (Sigma, St Louis, MO) at 72 hour intervals together 
with transfection 25 mmol/l of annealed short activating RNA 
oligonucleotide targeted to MafA (OmniCyte, London, UK) 
using Nanofectamine (PAA, Somerset, UK) following the 
manufacturer’s instructions. This process was repeated three 
times at days 2, 5, and 8.
Isolation of total RNA. Total RNA extraction was carried out on 
non-adherent differentiated cells using the RNAqueous-Micro 
kit (Ambion, Paisley, UK) following the manufacturer’s instruc-
tions. Briefly, the cells were gently centrifuged followed by 
three pulses of sonication at Output 3 in Lysis buffer (Ambion). 
The cell lysates were then processed through an RNA bind-
ing column, followed by multiple washes and elution. The total 
RNA isolated was quantified by a Nanodrop 2000 spectropho-
tometer (Thermo Scientific, Wilmington, DE).
For semi-quantitative RT-PCR. Total RNA of 500 ηg was 
reversed transcribed using One Step RT-PCR (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions. 
Expression for PDX1, RFX6, MafA, insulin, and for loading 
control, the house keeping gene actin was performed by 
PCR using their respective primer pairs: PDX1- F: CGG AAG 
AAA AAG AGC CAT TG; R: GCC AGA GGA AGA GGA GGA 
CT following 59 cycles at 95 °C, 20 seconds; 60 °C, 20 sec-
onds; 72 °C, 40 seconds. Rfx6- F: AAT GGC AGG GAG GCC 
CCC AA; R: CTG GGC TTG CAG GGA TGG GC following 39 
cycles at 95 °C, 30 seconds; 55 °C, 30 seconds; 65 °C, 45 
seconds. MafA-F: AGC TGG TGT CCA TGT CGG TGC G; R: 
TGG CAC TTC TCG CTC TCC AGA ATG T following 39 
cycles at 95 °C, 45 seconds; 67.4 °C, 45 seconds; 72 °C, 
45 seconds. Insulin (nested cycle, previously described)42-F: 
GAC CTA CTG CCA CAA CAG CTA; R: GTT GCA GTA GTT 
CTC CAG CTG; following 40 cycles at 95 °C, 1 minute; 55 °C, 
1 minute; 70 °C, 1 minute. For the nested step using 
F(nested): CTG TCC TTC TGC CAT GG; following 35 cycles 
at 50 °C, 1 minute; 95 °C, 1 minute; 58 °C, 45 seconds; 68 °C, 
45 seconds in at 35 cycles. Actin-F: GAG AAA ATC TGG CAC 
CAC ACC; R: ATA CCC CTC GTA GAT GGG CAC following 
37 cycles at 95 °C, 5 minutes; 60 °C, 30 seconds; 70 °C, 45 
seconds; 72 °C, 10 minutes at 37 cycles.
For quantitative RT-PCR. Total extracted RNA of 500 ηg was 
processed for elimination of genomic DNA followed by reverse 
transcription using the QuantiTect Reverse Transcription kit 
from Qiagen. The first strand cDNA synthesis was then ampli-
fied for quantitative analysis of PDX1 (NM_000209), Neu-
rogenin 3 (NM_020999), NeuroD (NM_002500), NKX6-1 
(NM_006168), MafA (NM_201589), glucokinase (NM_000162, 
NM_033507, NM_033508), GLP1R (NM_002062), SUR1, 
K-ATP component, ABCC8 (NM_000352), phogrin (protein 
tyrosine phosphatase receptor (N-terminal polypeptide 2), 
PTPRN2 (NM_002847, NM_130842, NM_130843), pro-Insu-
lin (NM_000207, NM_001185097, NM_001185098), and the 
reference gene, human gluceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) (NM_002046) using QuantiFast SYB-
RGreen PCR Kit from Qiagen. Amplification was performed 
using Applied Biosystems 7900HT FAST-Real-Time System 
(Applied Biosystems, Paisley, UK) with 40 cycle conditions at 
95 °C, 15 seconds and 60 °C, 45 seconds with a total volume 
of 25 μl per sample. Amplified products were then analyzed 
using Applied Biosystems RQ Manager 1.2.1. Four indepen-
dent experiments were amplified in triplicates for quantitative 
analysis. Student’s t-test scoring was performed at 99% con-
fidence intervals.
Confocal microscopy. CD34+ cells were fixed for 20 minutes 
with 4% paraformaldehyde onto 1 cm glass cover slips followed 
by permeabilization with 0.2% TritonX100 for 15 minutes. 
The coverslips were washed three times with PBS  followed 
by blocking with 5% mouse or rabbit serum for 45 minutes. 
Mouse raised anti-human insulin (1:200) (Sigma, Poole, UK) 
or rabbit raised anti-human C-peptide (1:200) (Abcam, Cam-
bridge, UK), was added to the cells in 5% serum for 1 hour. 
Cells were washed three times in PBS followed by the addi-
tion of 5% serum for a further 15 minutes before incubation 
with the appropriate Alexa-488 conjugated or  Alexa-594 
secondary antibody (1:600) (Cell Signalling Technology, 
 Hertfordshire, UK) for 1 hour. After five washes in PBS, cover-
slips were mounted onto glass slides with Vectashield contain-
ing 4′6′-diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, CA). Slides were visualized on a Leica DM4000 
at 60× magnification or Olympus epiflourescent CKX41 micro-
scope. An average of five images was captured and compared 
with staining with the secondary conjugated antibody alone to 
confirm no presence of autofluorescence.
Insulin and C-peptide ELISA. MafA-transfected cells growing 
in suspension to day 12 were transferred to a preconditioning 
α-MEM media supplemented with 10 mmol/l nicotinamide, 
50 ηg IGF-II, 10 ηg HGF, 25 ηg exendin-4, and 10 ηg activin 
A. Cells were incubated for 16 hours at 37 °C and 5% CO2 
before glucose stimulation. Glucose of 2.8 mmol/l was added 
for 3 hours followed by 16 mmol/l of glucose for a further 
3 hours. The media was collected for total human insulin or 
human C-peptide ELISA (Millipore, Billerica, MA) following 
the manufacturer’s instructions. Positive control used was as 
supplied by the kit.
Fluorescence-activated cell sorting analysis. Approximately 
3 × 106 of day 12 differentiated CD34+ cells were fixed and 
permeabilized using Fix&Perm fixation medium (Caltag Lab-
oratories, Burlingame, CA) following the manufacturer’s pro-
tocol. Briefly, after washing the cells in PBS, 100 μl of reagent 
A (fixation medium) were added and the cells were incubated 
for 15 minutes at room temperature. At the end of the incu-
bation, the cells were washed in PBS then 100 μl of reagent 
B (permeabilization medium) were added for 15 minutes at 
room temperature. The cells were then resuspended in block-
ing buffer comprising PBS, with 5% fetal calf serum and 3% 
bovine serum albumin and incubated for 15 minutes. Cells 
were then incubated with antibodies against insulin (Abcam) 
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(1:350) and C-peptide (Santa Cruz Biotechnology, Dallas, 
TX) (1:350) for 1 hour. After a wash in 3% FBS/1% bovine 
serum albumin in PBS (wash solution), cells were incubated 
with 1 μg/ml goat anti-mouse Alexa Fluor-488 (green), goat 
anti-rabbit Alexa Fluor-488 (green), and goat anti-rabbit 
Alexa Fluor-647 (red) (all Invitrogen) in blocking solution for 
45 minutes in the dark, washed with PBS and resuspended in 
PBS for flow cytometric analysis. Stained cells were analyzed 
using the BD LSRII flow cytometer with 525_50 B-A and APC 
lasers to view the Alexa Fluors-488 and 647 respectively. At 
least 10,000 cells were collected for each test sample to 
ensure a sufficient number of positive stained cells. FlowJo 
7.6 software (FlowJo, Ashland, OR) was used for the analy-
sis of the results (Supplementary Materials and Methods).
Supplementary material
Figure S1. (a) An insulin and C-peptide ELISA assay of 
 MafA-transfected cells.
Figure S2. Individual and merged (in color) histograms of 
fluorescence-activated cell sorting analyzed cells probed 
with (a) anti-insulin or (b) anti-C-peptide.
Figure S3. A high magnification immunostaining of insulin 
and C-peptide in MafA-transfected cells with glucose treat-
ment and control cells (undifferentiated CD34+ cells).
Materials and Methods
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